CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly ...

高级别胶质瘤（HGGs） 是指恶性程度较高的脑胶质瘤，其生长迅速、病情进展较快、预后较差，5年生存率低于5%。最恶性的高级别胶质瘤包括 IV级异柠檬酸脱氢酶 (IDH)野生型胶质母细胞瘤（GBM） 和 IV级IDH突变型星形细胞瘤 。 蛋白基因组学 ...

This research uses deep learning models to uncover sex-specific survival predictors for high-grade gliomas (HGGs).

Definitive diagnosis of glioma requires a biopsy and pathology, including histology and molecular testing. A tissue biopsy ...

In a recent publication in the journal Cancer Cell, the Consortium focused on one of the deadliest types of cancer, high-grade gliomas, and provided the most detailed analysis of what is going on ...

A glioma is a type of tumor that originates in the central nervous system, specifically in the brain or spinal cord. These tumors originate in glial cells, supportive cells in the brain which serve to ...

Diffuse midline glioma (DMG) is a highly aggressive and fatal pediatric high-grade glioma that primarily affects critical regions of the central nervous system, such as the pons, thalamus ...

Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted ...